Key Points
- Jazz Pharmaceuticals CAO Patricia Carr sold 1,413 shares for $326,911.68, reducing her stake by 17.83% to 6,512 shares.
- The company beat quarterly estimates, reporting $1.24 billion in revenue versus $1.21 billion expected, with year-over-year revenue growth of 10.4%; it also raised its 2026 revenue outlook to about $4.78 billion–$4.85 billion.
- Analyst sentiment is broadly positive: Jazz has a “Moderate Buy” consensus rating and a $293.45 average price target. Shares opened at $234.76 and were reported up 3.3%.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CAO Patricia Carr sold 1,413 shares of the business's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total transaction of $326,911.68. Following the sale, the chief accounting officer directly owned 6,512 shares of the company's stock, valued at $1,506,616.32. This represents a 17.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Jazz Pharmaceuticals Trading Up 3.3%
Shares of JAZZ stock opened at $234.76 on Friday. The stock has a market capitalization of $15.24 billion, a P/E ratio of 79.85, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The company has a 50 day moving average price of $229.39 and a 200 day moving average price of $217.74. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.03) by $0.15. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.55%. The business's revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.13 earnings per share. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 10.88 EPS for the current fiscal year.
Jazz Pharmaceuticals News Summary
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
- Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
- Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the company. Piper Sandler lifted their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an "overweight" rating in a report on Tuesday, August 4th. Morgan Stanley lifted their price objective on shares of Jazz Pharmaceuticals from $314.00 to $319.00 and gave the company an "overweight" rating in a research note on Tuesday. Canaccord Genuity Group set a $300.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, August 26th. The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 24th. They set a "buy" rating and a $337.00 target price for the company. Finally, Citigroup started coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, September 30th. They issued a "buy" rating and a $325.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $293.45.
Check Out Our Latest Research Report on Jazz Pharmaceuticals
Hedge Funds Weigh In On Jazz Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in JAZZ. Bank of New York Mellon Corp grew its position in shares of Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company's stock valued at $317,485,000 after purchasing an additional 517,514 shares during the period. Bank of America Corp DE increased its holdings in Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company's stock worth $191,848,000 after buying an additional 99,656 shares during the last quarter. Systematic Financial Management LP raised its position in Jazz Pharmaceuticals by 2.6% during the first quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company's stock worth $76,965,000 after acquiring an additional 10,237 shares in the last quarter. Retirement Systems of Alabama increased its position in Jazz Pharmaceuticals by 7.6% during the 3rd quarter. Retirement Systems of Alabama now owns 171,801 shares of the specialty pharmaceutical company's stock worth $39,775,000 after buying an additional 12,138 shares during the period. Finally, Quantinno Capital Management LP increased its position in shares of Jazz Pharmaceuticals by 9.7% in the first quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company's stock worth $36,163,000 after purchasing an additional 16,928 shares during the period. 89.14% of the stock is owned by institutional investors.
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
